Imaging of nonprostate cancers using PSMA-targeted radiotracers: Rationale, current state of the field, and a call to arms

A. Salas Fragomeni Roberto, Tali Amir, Sara Sheikhbahaei, Susan C. Harvey, Mehrbod S. Javadi, Lilja B. Solnes, Ana P. Kiess, Mohamad E. Allaf, Martin G. Pomper, Michael A. Gorin, Steven P. Rowe

Research output: Contribution to journalArticlepeer-review

Abstract

Prostate-specific membrane antigen (PSMA) is a type II transmem-brane glycoprotein that is highly overexpressed on prostate cancer epithelial cells and for which there is a growing body of literature examining the role of small-molecule and antibody radiotracers targeted against this protein for prostate cancer detection and therapy. Despite its name, PSMA is also expressed, to varying degrees, in the neovasculature of a wide variety of nonprostate cancers; indeed, the pathology literature is replete with promising immunohistochemistry findings. Several groups have begun to correlate those pathology-level results with in vivo imaging and therapy in nonprostate cancers using the same PSMA-targeted agents that have been so successful in prostate cancer. The potential to leverage radiotracers targeted to PSMA beyond prostate cancer is a promising approach for many cancers, and PSMA-targeted agents may be able to supplement or fill gaps left by other agents. However, to date, most of the reported findings with PSMA-targeted radiotracers in nonprostate malignancies have been in case reports and small case series, and the field must adopt a more thorough approach to the design and execution of larger prospective trials to realize the potential of these promising agents outside prostate cancer.

Original languageEnglish (US)
Pages (from-to)871-877
Number of pages7
JournalJournal of Nuclear Medicine
Volume59
Issue number6
DOIs
StatePublished - Jun 1 2018

Keywords

  • Breast cancer
  • Lung cancer
  • PET
  • PSMA
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Imaging of nonprostate cancers using PSMA-targeted radiotracers: Rationale, current state of the field, and a call to arms'. Together they form a unique fingerprint.

Cite this